IFNB1 and myeloid sarcoma: IL17 serum levels before treatment with IFN−β, as well as 3 months after treatment, could not be correlated to disease activity parameters in a cohort of 118 MS patients [37], and IL‐17 levels showed a trend towards being higher in MS patients with inactive disease compared to those with active disease in another patient cohort of 169 patients [38].